These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11704767)

  • 21. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies.
    Sørensen HT; Lash TL; Rothman KJ
    Hepatology; 2006 Nov; 44(5):1075-82. PubMed ID: 17058242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medscape psychopharmacology today: understanding clinical trials in context.
    Kramer TA
    MedGenMed; 2003 Oct; 5(4):2. PubMed ID: 14745349
    [No Abstract]   [Full Text] [Related]  

  • 25. Randomized trials vs. historical controls: the scientific plagues of both houses.
    Feinstein AR; Wells CK
    Trans Assoc Am Physicians; 1977; 90():239-47. PubMed ID: 347675
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical prediction rules.
    Maher C
    Phys Ther; 2006 May; 86(5):759; author reply 760. PubMed ID: 16649899
    [No Abstract]   [Full Text] [Related]  

  • 27. Diet and cancer: the disconnect between epidemiology and randomized clinical trials.
    Meyskens FL; Szabo E
    Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1366-9. PubMed ID: 15941942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An overview of study design.
    Cardwell JM
    J Small Anim Pract; 2008 May; 49(5):217-8. PubMed ID: 18445164
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues.
    Sankoh AJ; D'Agostino RB; Huque MF
    Stat Med; 2003 Oct; 22(20):3133-50. PubMed ID: 14518019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overhauling clinical trials.
    Scott CT; Baker M
    Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
    [No Abstract]   [Full Text] [Related]  

  • 31. The use and misuse of N-of-one studies.
    O'Brien PC
    Int J Oral Maxillofac Implants; 1997; 12(3):293. PubMed ID: 9197093
    [No Abstract]   [Full Text] [Related]  

  • 32. Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents.
    Steensma DP
    Am J Hematol; 2008 Sep; 83(9):693-4. PubMed ID: 18615451
    [No Abstract]   [Full Text] [Related]  

  • 33. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS-II): prologue to COURAGE.
    King SB
    Circulation; 2007 Mar; 115(9):1064-6. PubMed ID: 17339563
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment allocation in clinical trials.
    Webert KE
    Transfusion; 2007 Dec; 47(12):2187-8. PubMed ID: 17714423
    [No Abstract]   [Full Text] [Related]  

  • 35. [Interpretation of epidemiologic studies].
    Schaffer P; Velten M
    Rev Prat; 2002 May; 52(10):1131-7. PubMed ID: 12107937
    [No Abstract]   [Full Text] [Related]  

  • 36. [The GOSPEL study].
    Volterrani M; Agostoni P
    G Ital Cardiol (Rome); 2009 Jul; 10(7):419-21. PubMed ID: 19761099
    [No Abstract]   [Full Text] [Related]  

  • 37. A 25-year review of sequential methodology in clinical studies.
    Todd S
    Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gatekeeping procedures with clinical trial applications.
    Dmitrienko A; Tamhane AC
    Pharm Stat; 2007; 6(3):171-80. PubMed ID: 17583553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, Statistics in Medicine, DOI: 10.1002/sim.2855.
    Koch GG
    Stat Med; 2008 Feb; 27(3):333-42. PubMed ID: 17530625
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.